Supplementary Figure 5 from Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity

figure

posted on 2023-06-27, 14:20 authored by Hong Jiang, Dong Ho Shin, Yanhua Yi, Xuejun Fan, Joy Gumin, Jiasen He, Andrew G. Gillard, Frederick F. Lang, Candelaria Gomez-Manzano, Juan Fueyo

Expression of CD3 and CD8 on CD45+ leukocytes from B16F10-RFLuc-3 tumors. Delta-24-RGDOX was injected into the s.c. tumors on Days 8, 11 and 14. Leukocytes from the tumors were profiled through flow cytometry on Day 18. RGDOX: Delta-24-RGDOX.

Funding

HHS | NIH | NCI | National Cancer Institute (NCI)

The University Cancer Foundation via the Institution Research Grant program at The University of Texas MD Anderson Cancer Center

the John and Rebekah Harper Fellowship

History

ARTICLE ABSTRACT

Adjuvant therapy with oncolytic viruses promotes antigen spread to potentiate localized intratumoral adoptive T-cell therapy with limited TAA targets, leading to sustainable systemic antitumor immunity to overcome tumor relapse.